Repligen Co. (NASDAQ:RGEN) Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its stake in Repligen Co. (NASDAQ:RGEN) by 14.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,879 shares of the biotechnology company’s stock after purchasing an additional 992 shares during the period. Pictet Asset Management Holding SA’s holdings in Repligen were worth $1,134,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. UMB Bank n.a. lifted its position in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in shares of Repligen in the 4th quarter valued at approximately $216,000. Worldquant Millennium Advisors LLC lifted its holdings in shares of Repligen by 11.9% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company’s stock valued at $7,482,000 after buying an additional 5,337 shares during the period. Van ECK Associates Corp boosted its stake in shares of Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock valued at $6,078,000 after buying an additional 3,066 shares in the last quarter. Finally, Stephens Investment Management Group LLC grew its holdings in Repligen by 7.4% during the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock worth $77,267,000 after acquiring an additional 37,057 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on RGEN shares. Royal Bank of Canada boosted their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. Canaccord Genuity Group began coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective on the stock. TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Finally, StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $178.64.

Insider Buying and Selling

In other Repligen news, Director Margaret Pax purchased 250 shares of Repligen stock in a transaction on Monday, March 17th. The shares were bought at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is owned by company insiders.

Repligen Stock Down 8.0 %

Shares of NASDAQ:RGEN opened at $111.94 on Friday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $6.29 billion, a P/E ratio of -219.49, a P/E/G ratio of 4.54 and a beta of 0.95. Repligen Co. has a 52-week low of $106.78 and a 52-week high of $182.52. The stock’s fifty day simple moving average is $150.03 and its 200-day simple moving average is $147.58.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, equities research analysts forecast that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.